Is Obio Technology (Shanghai) (SHSE:688238) Using Too Much Debt?
Is Obio Technology (Shanghai) (SHSE:688238) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We note that Obio Technology (Shanghai) Corp., Ltd. (SHSE:688238) does have debt on its balance sheet. But is this debt a concern to shareholders?
有人说,波动性,而不是债务,是投资者思考风险的最佳方式,但沃伦·巴菲特曾说过一句名言:“波动性远非风险的代名词。”当我们思考一家公司的风险有多大时,我们总是喜欢考虑其债务的用途,因为债务过载可能导致破产。我们注意到,奥比奥科技(上海)股份有限公司(上海证券交易所股票代码:688238)的资产负债表上确实有债务。但是这笔债务是股东关心的问题吗?
Why Does Debt Bring Risk?
为什么债务会带来风险?
Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. While that is not too common, we often do see indebted companies permanently diluting shareholders because lenders force them to raise capital at a distressed price. Of course, plenty of companies use debt to fund growth, without any negative consequences. The first step when considering a company's debt levels is to consider its cash and debt together.
债务可以帮助企业,直到企业难以偿还债务,无论是新资本还是自由现金流。最终,如果公司无法履行偿还债务的法律义务,股东可能会一无所获。尽管这种情况并不常见,但我们经常会看到负债公司永久稀释股东,因为贷款人迫使他们以不良价格筹集资金。当然,许多公司使用债务为增长提供资金,而不会产生任何负面影响。考虑公司的债务水平的第一步是同时考虑其现金和债务。
What Is Obio Technology (Shanghai)'s Debt?
Obio Technology(上海)的债务是多少?
The image below, which you can click on for greater detail, shows that at September 2023 Obio Technology (Shanghai) had debt of CN¥193.7m, up from CN¥49.4m in one year. However, its balance sheet shows it holds CN¥779.4m in cash, so it actually has CN¥585.7m net cash.
您可以点击下图查看更多详情,该图片显示,截至2023年9月,奥比奥科技(上海)的债务为1.937亿元人民币,高于一年的4,940万元人民币。但是,其资产负债表显示其持有7.794亿元的现金,因此实际上拥有5.857亿元人民币的净现金。
A Look At Obio Technology (Shanghai)'s Liabilities
看看奥比奥科技(上海)的负债
Zooming in on the latest balance sheet data, we can see that Obio Technology (Shanghai) had liabilities of CN¥261.4m due within 12 months and liabilities of CN¥239.7m due beyond that. Offsetting these obligations, it had cash of CN¥779.4m as well as receivables valued at CN¥106.2m due within 12 months. So it can boast CN¥384.5m more liquid assets than total liabilities.
放大最新的资产负债表数据,我们可以看到,Obio Technology(上海)在12个月内到期的负债为2.614亿元人民币,之后到期的负债为2.397亿元人民币。除了这些债务外,它还有7.794亿元的现金以及价值1.062亿元人民币的应收账款将在12个月内到期。因此,它拥有的流动资产可以多出3.845亿元人民币 总 负债。
This surplus suggests that Obio Technology (Shanghai) has a conservative balance sheet, and could probably eliminate its debt without much difficulty. Simply put, the fact that Obio Technology (Shanghai) has more cash than debt is arguably a good indication that it can manage its debt safely. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately the future profitability of the business will decide if Obio Technology (Shanghai) can strengthen its balance sheet over time. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.
这种盈余表明Obio Technology(上海)的资产负债表比较保守,可以毫不费力地消除债务。简而言之,Obio Technology(上海)的现金多于债务这一事实可以说是一个很好的迹象,表明它可以安全地管理债务。在分析债务水平时,资产负债表是显而易见的起点。但最终,该业务未来的盈利能力将决定Obio Technology(上海)能否随着时间的推移加强其资产负债表。因此,如果你想看看专业人士的想法,你可能会发现这份关于分析师利润预测的免费报告很有趣。
In the last year Obio Technology (Shanghai) had a loss before interest and tax, and actually shrunk its revenue by 27%, to CN¥213m. That makes us nervous, to say the least.
去年,奥比奥科技(上海)在利息和税前出现亏损,实际上其收入减少了27%,至2.13亿元人民币。至少可以说,这让我们感到紧张。
So How Risky Is Obio Technology (Shanghai)?
那么奥比奥科技(上海)的风险有多大?
By their very nature companies that are losing money are more risky than those with a long history of profitability. And we do note that Obio Technology (Shanghai) had an earnings before interest and tax (EBIT) loss, over the last year. And over the same period it saw negative free cash outflow of CN¥730m and booked a CN¥128m accounting loss. Given it only has net cash of CN¥585.7m, the company may need to raise more capital if it doesn't reach break-even soon. Overall, its balance sheet doesn't seem overly risky, at the moment, but we're always cautious until we see the positive free cash flow. When we look at a riskier company, we like to check how their profits (or losses) are trending over time. Today, we're providing readers this interactive graph showing how Obio Technology (Shanghai)'s profit, revenue, and operating cashflow have changed over the last few years.
就其本质而言,亏损的公司比盈利历史悠久的公司风险更大。而且我们确实注意到,Obio Technology(上海)去年出现了息税前收益(EBIT)亏损。同期,它的自由现金流出为负7.3亿元人民币,会计亏损为1.28亿元人民币。鉴于其净现金仅为5.857亿元人民币,如果不能很快达到收支平衡,该公司可能需要筹集更多资金。总体而言,其资产负债表目前似乎风险不大,但在看到正自由现金流之前,我们始终保持谨慎。当我们研究一家风险较高的公司时,我们喜欢检查他们的利润(或亏损)随着时间的推移而呈现的趋势。今天,我们向读者提供这张交互式图表,显示奥比奥科技(上海)的利润、收入和运营现金流在过去几年中发生了怎样的变化。
Of course, if you're the type of investor who prefers buying stocks without the burden of debt, then don't hesitate to discover our exclusive list of net cash growth stocks, today.
当然,如果你是那种喜欢在没有债务负担的情况下购买股票的投资者,那么请立即查看我们的独家净现金增长股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。